Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Brenipatide in Adults With IBS-C
jRCT2031260143Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing LY3537031 (Brenipatide) with Placebo (2 arms). Primary endpoint: Percentage of participants with a weekly composite clinical response for at least 50% of weeks (Weeks 9–16). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
brenipatide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on jRCT2031260143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260143.